Author:
Hales R.K.,Banchereau J.,Ribas A.,Tarhini A.A.,Weber J.S.,Fox B.A.,Drake C.G.
Reference44 articles.
1. Assessing tumor-related signs and symptoms to support cancer drug approval;Williams;J Biopharm Stat,2004
2. Food and Drug Administration requirements for approval of new anticancer drugs;Johnson;Cancer Treat Rep,1985
3. US Food and Drug Administration. CFR—Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch2.cfm?CFRPart=314. (6 August 2009, date last accessed).
4. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors;Dagher;Clin Cancer Res,2002
5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献